Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults

Trial Profile

Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2015

At a glance

  • Drugs Enterovirus A vaccine (Primary)
  • Indications Coxsackievirus infections; Enterovirus A infections
  • Focus Adverse reactions
  • Sponsors Inviragen
  • Most Recent Events

    • 11 Mar 2012 Complete safety and immunogenicity results will be reported at an infectious disease meeting in 2012, according to an Inviragen media release.
    • 11 Mar 2012 Status changed from active, no longer recruiting to completed, according to an Inviragen media release.
    • 27 Sep 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top